Business

Third Rock Ventures launches Ember Therapeutics

Third Rock Ventures LLC, a venture capital firm with offices in Boston, announced the formation of Ember Therapeutics with a $34 million Series A financing.

In a press release, Ember said it looks to leverage findings in brown-fat biology and recent breakthroughs in selective insulin sensitivity to develop treatments for metabolic diseases, including Type 2 diabetes and obesity.

Advertisement

The plan is for some of Ember’s early drug candidates to “augment and activate the body’s brown fat, amplifying the natural ability to efficiently burn fuel stores such as glucose and lipids to reduce stored calories in the body,” the release said. 

Ember’s founders are Bruce Spiegelman, a professor of cell biology at Dana Farber Cancer Institute and Harvard Medical School; Patrick Griffin, chairman and professor of the department of molecular therapeutics at the Scripps Research Institute; and C. Ronald Kahn, M.D., professor of medicine at the Joslin Diabetes Center and the Harvard Medical School, along with Third Rock Ventures, the company said.

Ember’s interim chief executive is Louis Tartaglia, a partner at Third Rock Ventures.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.